ApicHope Pharmaceutical Co., Ltd
SZSE:300723.SZ
26.51 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,450.23 | 2,503.447 | 2,280.199 | 2,199.214 | 1,675.417 | 1,637.406 | 1,429.554 | 1,380.217 | 1,250.837 | 1,028.297 | 792.555 | 507.567 |
| Cost of Revenue
| 560.532 | 474.581 | 300.204 | 318.462 | 295.427 | 367.03 | 393.473 | 579.91 | 599.391 | 478.768 | 391.438 | 316.614 |
| Gross Profit
| 889.698 | 2,028.866 | 1,979.995 | 1,880.753 | 1,379.99 | 1,270.375 | 1,036.082 | 800.308 | 651.446 | 549.53 | 401.117 | 190.953 |
| Gross Profit Ratio
| 0.613 | 0.81 | 0.868 | 0.855 | 0.824 | 0.776 | 0.725 | 0.58 | 0.521 | 0.534 | 0.506 | 0.376 |
| Reseach & Development Expenses
| 312.087 | 301.368 | 189.78 | 142.323 | 135.344 | 98.049 | 91.381 | 81.069 | 46.967 | 30.557 | 40.321 | 18.494 |
| General & Administrative Expenses
| 89.807 | 131.89 | 64.083 | 52.511 | 18.879 | 28.088 | 29.892 | 25.779 | 14.483 | 44.876 | 11.799 | 36.08 |
| Selling & Marketing Expenses
| 454.394 | 1,122.52 | 1,248.854 | 1,281.679 | 934.458 | 851.112 | 614.077 | 439.477 | 371.633 | 328.302 | 245.882 | 100.771 |
| SG&A
| 544.2 | 1,255.393 | 1,312.936 | 1,334.191 | 953.337 | 879.199 | 643.97 | 465.255 | 386.116 | 373.178 | 257.682 | 136.85 |
| Other Expenses
| 404.126 | 258.176 | 31.97 | 101.449 | 74.744 | 6.79 | 8.878 | 3.348 | 22.681 | 1.634 | 2.227 | -0.376 |
| Operating Expenses
| 1,260.413 | 1,814.936 | 1,646.04 | 1,601.94 | 1,181.56 | 1,044.142 | 796.663 | 596.521 | 488.859 | 444.518 | 326.101 | 140.196 |
| Operating Income
| -370.715 | 213.93 | 281.974 | 285.282 | 198.554 | 182.267 | 234.83 | 181.697 | 141.801 | 80.82 | 52.858 | 43.709 |
| Operating Income Ratio
| -0.256 | 0.085 | 0.124 | 0.13 | 0.119 | 0.111 | 0.164 | 0.132 | 0.113 | 0.079 | 0.067 | 0.086 |
| Total Other Income Expenses Net
| -274.996 | 30.255 | 44.439 | 77.489 | 74.744 | 6.79 | 8.878 | 3.348 | 22.386 | 1.454 | 2.18 | -0.397 |
| Income Before Tax
| -645.711 | 244.185 | 326.414 | 362.771 | 273.298 | 189.057 | 243.708 | 185.045 | 164.187 | 82.274 | 55.037 | 43.312 |
| Income Before Tax Ratio
| -0.445 | 0.098 | 0.143 | 0.165 | 0.163 | 0.115 | 0.17 | 0.134 | 0.131 | 0.08 | 0.069 | 0.085 |
| Income Tax Expense
| -79.004 | 92.39 | 64.317 | 69.357 | 49.662 | 46.528 | 36.022 | 30.226 | 28.345 | 21.873 | 15.839 | 10.988 |
| Net Income
| -540.039 | 184.613 | 290.683 | 306.915 | 225.611 | 143.686 | 208.224 | 156.695 | 137.35 | 60.42 | 40.31 | 32.994 |
| Net Income Ratio
| -0.372 | 0.074 | 0.127 | 0.14 | 0.135 | 0.088 | 0.146 | 0.114 | 0.11 | 0.059 | 0.051 | 0.065 |
| EPS
| -1.2 | 0.42 | 0.69 | 0.71 | 0.52 | 0.33 | 0.48 | 0.47 | 0.42 | 0.19 | 0 | 0 |
| EPS Diluted
| -1.2 | 0.42 | 0.69 | 0.71 | 0.52 | 0.33 | 0.48 | 0.47 | 0.42 | 0.19 | 0 | 0 |
| EBITDA
| -407.055 | 464.041 | 448.316 | 498.783 | 326.85 | 232.628 | 297.285 | 234.185 | 213.999 | 143.48 | 92.974 | 64.143 |
| EBITDA Ratio
| -0.281 | 0.185 | 0.197 | 0.227 | 0.195 | 0.142 | 0.208 | 0.17 | 0.171 | 0.14 | 0.117 | 0.126 |